ARYx Therapeutics, which re-engineers commercially successful drugs to eliminate safety issues, now plans to offer 5 million shares at $10 as opposed to the originally planned $14 to $16 range. The company plans to use the proceeds for research and development. Morgan Stanley is the lead manager on the deal.
